Development of high affinity selective VIP1 receptor agonists.
about
Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptideVPAC receptors for VIP and PACAPRoles for pituitary adenylate cyclase-activating peptide (PACAP) expression and signaling in the bed nucleus of the stria terminalis (BNST) in mediating the behavioral consequences of chronic stress.Vasoactive intestinal polypeptide (VIP) phase-shifts the rat suprachiasmatic nucleus clock in vitro.Pituitary adenylate cyclase-activating polypeptide stimulates glucose production via the hepatic sympathetic innervation in rats.Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide.Pituitary adenylate cyclase activating polypeptide (PACAP) signalling exerts chondrogenesis promoting and protecting effects: implication of calcineurin as a downstream target.Regulatory peptide receptors in human hepatocellular carcinomas.Pharmacological properties of Chinese hamster ovary cells coexpressing two vasoactive intestinal peptide receptors (hVPAC1 and hVPAC2)A structure-function study of PACAP using conformationally restricted analogs: Identification of PAC1 receptor-selective PACAP agonistsPituitary Adenylate Cyclase Activating Polypeptide (PACAP) Pathway Is Induced by Mechanical Load and Reduces the Activity of Hedgehog Signaling in Chondrogenic Micromass Cell Cultures.Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumorsRhythmic control of activity and sleep by class B1 GPCRs.Inhibition of interferon (IFN) gamma-induced Jak-STAT1 activation in microglia by vasoactive intestinal peptide: inhibitory effect on CD40, IFN-induced protein-10, and inducible nitric-oxide synthase expression.Pituitary adenylate cyclase-activating polypeptide (PACAP) signalling enhances osteogenesis in UMR-106 cell line.Receptors for NPY and PACAP differ in expression and activity during adipogenesis in the murine 3T3-L1 fibroblast cell lineA natural variant type II G protein-coupled receptor for vasoactive intestinal peptide with altered function.Evidence for a direct interaction between the Thr11 residue of vasoactive intestinal polypeptide and Tyr184 located in the first extracellular loop of the VPAC2 receptor.Rat and guinea pig pancreatic acini possess both VIP(1) and VIP(2) receptors, which mediate enzyme secretion.Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor kappaB and Ets activation.Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun.VPAC Receptor Subtypes Tune Purinergic Neuron-to-Glia Communication in the Murine Submucosal Plexus.VIP and PACAP are autocrine factors that protect the androgen-independent prostate cancer cell line PC-3 from apoptosis induced by serum withdrawal.Two tyrosine residues in the first transmembrane helix of the human vasoactive intestinal peptide receptors play a role in supporting the active conformation.Characterization of a novel VPAC(1) selective agonist and identification of the receptor domains implicated in the carboxyl-terminal peptide recognition.Role of endogenous PACAP in catecholamine secretion from the rat adrenal gland.Transglutaminase-mediated polyamination of vasoactive intestinal peptide (VIP) Gln16 residue modulates VIP/PACAP receptor activity.Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.Effects of vasoactive intestinal polypeptide on neurones of the rat suprachiasmatic nuclei in vitro.VPAC1 and VPAC2 receptor activation on GABA release from hippocampal nerve terminals involve several different signalling pathways.Pituitary adenylate cyclase-activating polypeptide receptors in the trigeminovascular system: implications for migraine.Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain.VIP and PACAP 38 modulate ibotenate-induced neuronal heterotopias in the newborn hamster neocortex.A complete substitutional analysis of VIP for better tumor imaging properties.
P2860
Q28143861-D3156134-48A4-4A64-B042-B79D58145E4BQ28203262-3CD96A2A-CD98-4B4C-A6DF-53E540516A3CQ30473327-17AC57FE-D564-4FE2-A711-1676265C257DQ32028034-B72EC7A6-6624-42F5-BA7B-5A95192AA9AAQ33930193-DCF5A8D3-6A20-4252-8D66-E6C38D828B34Q33950137-48548544-767A-46F1-9129-EE56DD15AEA8Q35124232-B6A99965-FAE5-4856-9428-DBD4B71AF0D6Q35357724-0823B5A6-998A-4DFB-9310-8AB1776021C9Q35546451-5FB6A0AF-667D-4119-B6AD-69A56D7AA069Q35572290-AAD577C4-2F3D-47BB-AC60-E25EF8A153A9Q36088456-E3D91D60-3072-47DE-91CB-996BA51B0E11Q36153216-10ED90F4-06B0-4C81-ADBB-B72A92EA0807Q36224883-7E4CAA4C-7110-4958-8ECD-001AA70CF06FQ38269733-A9F4E09B-50F3-4F97-9102-90D70FC46F37Q38354522-0E63D15D-0751-4025-B3CA-BFCCA85A0C46Q38967086-B4A7448B-3072-423E-AFE1-B4728AFD2A9FQ39855464-57136CB0-6E87-4B66-BBEC-1F2A4F41DD75Q40526986-CC153045-EDE4-4720-9D87-7B28FBAE89C5Q40684294-4DA6F546-3159-4195-BF84-C4CAC5ACBDDCQ40781276-4308DA63-9349-4461-BFF1-8638D33C570CQ40920235-B429237E-2B3E-4E77-8F53-9DE84190E5ECQ40995215-B8932EC7-FB40-46E9-A383-D1DAC5ABCC74Q42114871-36A7E824-18F9-4470-94DF-C95F755DB0C7Q42162928-5053BF66-EC40-433E-AEF3-97A8B1A08A90Q42176293-4DD91F77-CBB0-43AE-B7CF-EC64894C9E5DQ42782257-DA18987F-6234-44B2-A7DA-B58F19CE15EAQ43771199-DCB3ABE4-BAAF-4FD3-9F81-79C594F98682Q44041402-DAE0A3E5-64EF-42DA-A3E2-9672F77675E7Q44060393-F6983ECF-8124-4BCB-901E-7835CC31147CQ44086428-042A2C81-8060-45C9-9185-4B31F0716BBBQ47748308-CB7C2640-3EF3-4D11-BE08-253438A9AC98Q48034068-5DDDEB1A-FC1D-41D4-A08F-F219C22B5B4BQ48295110-21BC3345-7B3F-4810-B5BC-43113B9B4967Q49115803-36F41A1B-DFFD-45F0-A146-8DB53ED88102Q52955891-64A4D009-DE19-4982-BEDE-36B33E2193A1
P2860
Development of high affinity selective VIP1 receptor agonists.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Development of high affinity selective VIP1 receptor agonists.
@en
Development of high affinity selective VIP1 receptor agonists.
@nl
type
label
Development of high affinity selective VIP1 receptor agonists.
@en
Development of high affinity selective VIP1 receptor agonists.
@nl
prefLabel
Development of high affinity selective VIP1 receptor agonists.
@en
Development of high affinity selective VIP1 receptor agonists.
@nl
P2093
P1433
P1476
Development of high affinity selective VIP1 receptor agonists.
@en
P2093
Robberecht P
Vandermeers A
Vertongen P
Waelbroeck M
P304
P356
10.1016/S0196-9781(97)00228-3
P577
1997-01-01T00:00:00Z